Cargando…

Dexlansoprazole – a new-generation proton pump inhibitor

Dexlansoprazole modified release (MR) is an R-enantiomer of lansoprazole and a new-generation proton pump inhibitor exhibiting high efficacy in the treatment of symptoms and lesions associated with erosive oesophagitis caused by gastroesophageal reflux disease (GERD). The dual release of the active...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skrzydło-Radomańska, Barbara, Radwan, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2015
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697039/ https://www.ncbi.nlm.nih.gov/pubmed/26759624 http://dx.doi.org/10.5114/pg.2015.56109

Ejemplares similares

Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole
por: Mermelstein, Joseph, et al.
Publicado: (2016)

Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor – Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region
por: Goh, Khean Lee, et al.
Publicado: (2016)

How to Recognize and Treat Small Intestinal Bacterial Overgrowth?
por: Skrzydło-Radomańska, Barbara, et al.
Publicado: (2022)

Biomarkers of alcohol misuse: recent advances and future prospects
por: Jastrzębska, Iwona, et al.
Publicado: (2016)

Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion
por: Kwiatkowska, Brygida, et al.
Publicado: (2017)

The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review
por: Daniluk, Jaroslaw, et al.
Publicado: (2022)

Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis
por: Wittbrodt, Eric T, et al.
Publicado: (2009)

Amikacin/dexlansoprazole: Laryngitis: case report
Publicado: (2021)

Inflammatory fibroid polyp in the antrum co-occurring with adenomatous polyp in the ascending colon
por: Wronecki, Jakub, et al.
Publicado: (2018)

Self-Medication with Drotaverine among Patients with Common Abdominal Symptoms and Treatment Efficacy from the Perspectives of Patients and General Practitioners—An Observational, Retrospective, Cross-Sectional Study Using Real-World Data
por: Eder, Piotr, et al.
Publicado: (2022)

Managing gastroesophageal reflux disease – comparative efficacy and outcomes of dexlansoprazole MR
por: Frye, Jeanetta W, et al.
Publicado: (2015)

Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik
por: Pietrzak, Anna, et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
por: Kukulka, Michael, et al.
Publicado: (2016)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population?
por: Tayal, Rohit, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Proton pump inhibitors and colorectal cancer: A systematic review
por: Patel, Agastya, et al.
Publicado: (2021)

Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
por: Kuo, Chia-Jung, et al.
Publicado: (2019)

Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease
por: Gold, Benjamin D., et al.
Publicado: (2017)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Management of laryngopharyngeal reflux with proton pump inhibitors
por: Reimer, Christina, et al.
Publicado: (2008)

Problems Associated with Deprescribing of Proton Pump Inhibitors
por: Helgadottir, Holmfridur, et al.
Publicado: (2019)

Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified
por: Bruno, Giovanni, et al.
Publicado: (2019)

Proton pump inhibitors: A balanced view
por: Ramakrishna, B.S.
Publicado: (2015)

Risk of Pyogenic Liver Abscess in Proton Pump Inhibitor Users: New Inventory of Proton Pump Inhibitor Induced Complications?
por: Bang, Ki Bae
Publicado: (2021)

Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase
por: Lugini, Luana, et al.
Publicado: (2016)

Mechanisms of proton pump inhibitor‐induced hypomagnesemia
por: Gommers, Lisanne M. M., et al.
Publicado: (2022)

Proton pump inhibitors and dementia: what association?
por: Caetano, Catarina, et al.
Publicado: (2023)

Proton pump inhibitors as a risk factor for norovirus infection
por: PRAG, C., et al.
Publicado: (2017)

Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?
por: Rawla, Prashanth, et al.
Publicado: (2018)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

Proton pump inhibitors for the treatment of cancer in companion animals
por: Walsh, Megan, et al.
Publicado: (2015)

Antiplatelet agents and proton pump inhibitors – personalizing treatment
por: Lin, Eugene, et al.
Publicado: (2010)

Proton Pump Inhibitors: More Indigestion than Relief?
por: Malavade, P., et al.
Publicado: (2017)

Adverse Effects of Proton Pump Inhibitors—Evidence and Plausibility
por: Fossmark, Reidar, et al.
Publicado: (2019)

Proton Pump Inhibitor-Related Gastric Mucosal Changes
por: Kim, Gwang Ha
Publicado: (2021)

Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors
por: Janett, Simone, et al.
Publicado: (2015)

Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease
por: Kukulka, Michael, et al.
Publicado: (2014)

25 Years of Proton Pump Inhibitors: A Comprehensive Review
por: Strand, Daniel S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1th2cpfvtihtqqmcdcea0qodtl